Buy Signal on Genmab (GMAB-DK)
Genmab is a DKK 163.7 Bn market Biotech company which specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc.
Revenues are derived from :
1/ royalties (47%);
2/licences (45%) ;
3/ income from research and development and partnership agreementt (8%);
Denmark accounts for all net sales.
The company is expected to post a DKK 7.66 bn revenue in 2021 coupled with a net income of DKK 2 Bn. Revenue and results are expected to rise by 50% in 2022, while the company enjoy a DKK 14.6 Bn cash position.
At the end of 2020, the group had a portfolio of 18 products in clinical development phase and 20 in preclinical development phase.
• Genmab is collaborating with Seagen to launch tisotumab vedotin to treat cervical cancer.
• The market potential is below $1bn, but as the first commercial launch of an R&D behemoth, this is a substantial development, setting the stage for the rest of its pipeline.
Short term catalyst : Launch of tisotumab Vedotin in the US.
This signal looks consistent with the European Healthcare sector in Major Bullish Trend.